Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

NCT00219765 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Imatinib mesylate 600 mg
DRUG: Cytarabine
DRUG: Daunorubicine

Sponsor

Poitiers University Hospital

Collaborators

[object Object]
[object Object]